Dyspnea
Drug research and approvals for dyspnea: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 123 studies of dyspnea are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 123
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- The Effects of Wintergreen Essential Oil Inhalation on Alleviating Dyspnea Among Patients With PneumoniaNCT07894835 · Not applicable · Far Eastern Memorial Hospital · starts Oct 19, 2026
- A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During…NCT07881757 · Phase 3 · Pfizer · starts Oct 19, 2026
- Association of Inspiratory Effort With Dyspnea During Assisted Mechanical Ventilation in Critically Ill PatientsNCT07877350 · Not reported · University of Crete · starts Jun 18, 2026
- Comparative Effects of Coherent Breathing and Regular Paced Breathing on Dyspnea and Pulmonary Function in Patients…NCT07875036 · Not applicable · Foundation University Islamabad · starts Feb 11, 2026
- The Effect of Diaphragmatic Breathing Exercises on Pain, Dyspnea, Posture, Body Awareness, Anxiety, and Depression in…NCT07872163 · Not applicable · Alper Kemal Gürbüz · starts May 1, 2026
- Telerehabilitation Exercise Program for Postoperative Recovery in Lung Cancer.NCT07861282 · Not applicable · University of Seville · starts Sep 8, 2026
- The Effect of Progressive Muscle Relaxation Exercises on Fatigue, Dyspnea, and Respiratory Function in Patients With…NCT07842133 · Not applicable · University of Gaziantep · starts Apr 25, 2026
- A Continuation Study of Tilrekimig in Adults With Moderate-to-Severe Long-Term Breathing Difficulty, Known by the…NCT07839884 · Phase 3 · Pfizer · starts Oct 14, 2026
- Comparison of Arterial and Capillary Blood Gas Analyses in Patients With Respiratory Distress Due to COPD or APENCT07835945 · Not applicable · Centre Hospitalier Universitaire de Nice · starts Sep 28, 2026
Phase 3 4
- FentanylMu opioid receptor agonist
- MorphineMu opioid receptor agonist
- TolvaptanVasopressin V2 receptor antagonist
- NesiritideAtrial natriuretic peptide receptor A agonist
Phase 2 5
- FurosemideSodium-(potassium)-chloride cotransporter 2 inhibitor
- Nitric oxideSoluble guanylate cyclase activator
- DexamethasoneGlucocorticoid receptor agonist
- CaffeineAdenosine receptor antagonist
- Levodropropizine
Phase 1 or earlier 1
- OndansetronSerotonin 3a (5-HT3a) receptor antagonist
How its trials ended
518 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 99 whose ending is known, 42% met their primary endpoint, 12% missed it and 45% stopped early.
- Completed, result not reported24848%
- Ongoing9418%
- Status unknown7715%
- Met its primary endpoint428%
- Stopped: other or unclear275%
- Stopped: enrollment or feasibility133%
- Missed its primary endpoint122%
- Stopped: sponsor or business decision2<1%
- Stopped: funding2<1%
- Stopped: lack of efficacy1<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA